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Abstract
 
A somatic mutation in the X-linked phosphatidylinositol glycan class A (
 
PIGA
 
) gene causes the
loss of glycosyl phosphatidylinositol (GPI)-linked proteins on blood cells from patients with
paroxysmal nocturnal hemoglobinuria. Because all blood cell lineages may be affected it is
thought that the mutation occurs in a hematopoietic stem cell. In transgenic mice, germline
transmission of an inactive 
 
Piga 
 
gene is embryonic lethal. To inactivate the murine 
 
Piga
 
 gene in
early hematopoiesis we therefore chose conditional gene inactivation using the Cre/loxP sys-
tem. We expressed Cre recombinase under the transcription regulatory sequences of the hu-
man 
 
c-fes
 
 gene. FES-Cre inactivated PIGA in hematopoietic cells of mice carrying a floxed 
 
Piga
 
allele (LF mice). PIGA
 
 
 
 cells were found in all hematopoietic lineages of definitive but not
primitive hematopoiesis. Their proportions were low in newborn mice but subsequently in-
creased continuously to produce for the first time mice that have almost exclusively PIGA
 
 
 
blood cells. The loss of GPI-linked proteins occurred mainly in c-kit
 
 
 
CD34
 
 
 
Lin
 
 
 
 progenitor
cells before the CFU-GEMM stage. Using bone marrow reconstitution experiments with puri-
fied PIGA
 
 
 
 cells we demonstrate that LF mice have long-term bone marrow repopulating cells
that lack GPI-linked proteins, indicating that recombination of the floxed 
 
Piga
 
 allele occurs in
the hematopoietic stem cell.
Key words: hematopoiesis • stem cell • c-fes • paroxysmal nocturnal hemoglobinuria • 
conditional gene inactivation
 
Introduction
 
Paroxysmal nocturnal hemoglobinuria (PNH)
 
*
 
 is believed
to be a disease of the hematopoietic stem cell (HSC) (1, 2).
In patients with PNH, a somatic mutation occurs in the
X-linked 
 
PIGA
 
 (phosphatidylinositol glycan class A) gene
(3, 4). 
 
PIGA
 
 encodes a protein subunit of the 
 
 
 
-1-6-
 
N
 
-
acetylglucosaminyltransferase, an enzyme essential in the
biosynthesis of glycosyl phosphatidylinositol (GPI) mole-
cules (5). Therefore, in patients with PNH, a proportion of
blood cells lacks all surface proteins that use a GPI-anchor
molecule to attach to the cell membrane (PIGA
 
 
 
 cells) (6).
All blood cell lineages may be affected, including erythro-
cytes, granulocytes, monocytes, platelets, and lymphocytes.
Molecular analysis of 
 
PIGA
 
 gene mutations in the affected
blood cells demonstrated that PIGA
 
 
 
 cells are of clonal ori-
gin, indicating that the mutation occurs in a pluripotent
hematopoietic progenitor cell, possibly the HSC (3, 4).
Targeted mutagenesis of the murine 
 
Piga
 
 gene demon-
strated that inactivation of PIGA in murine embryonic
stem cells is lethal in very early embryonic development (7,
8). To limit PIGA inactivation to hematopoietic cells we
therefore employed conditional gene inactivation using the
Cre/loxP system (9–11)
 
 
 
and expressed the Cre recombi-
nase under the DNA sequences necessary for the transcrip-
tion of the human 
 
c-fes
 
 gene.
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GPI, glycosyl phosphatidylinositol;
HSC, hematopoietic stem cell; IRES, internal ribosome entry site; LCR,
locus control region; PIGA, phosphatidylinositol glycan class A; PNH,
paroxysmal nocturnal hemoglobinuria; 
 
wt
 
, wild-type. 
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Human 
 
c-fes
 
 encodes a 92-kD nonreceptor protein-
tyrosine kinase (FES) preferentially expressed in hemato-
poietic progenitor cells in the bone marrow and during
myeloid differentiation (12). FES expression remains high
during myelomonocytic differentiation (13), but decreases
upon maturation along the erythroid lineage (14). 
 
C-fes
 
messenger RNA has not been detected in lymphoid cells.
High level FES expression is also documented in vascular
endothelial cells (15). Inactivation of 
 
c-fes
 
 in mice resulted
in functional abnormalities of myelomonocytic cells, and
also suggested a role in B cell homeostasis (16, 17). During
embryonic development high levels of 
 
c-fes
 
 messenger
RNA were found in cells enriched for murine liver stem
cells (14, 18).
A 13-kb EcoRI genomic DNA fragment encompassing
the human 
 
c-fes
 
 gene (19) contains all regulatory DNA se-
quences required for a locus control region (LCR) with
myelomonocyte-specific expression in transgenic animals
(20, 21). We used the 
 
c-fes
 
 LCR to express the Cre recom-
binase. 
 
Fes-cre 
 
transgenic mice were crossbred with mice
carrying a floxed 
 
Piga
 
 allele. FES-Cre–mediated recombi-
nation of the floxed 
 
Piga
 
 allele caused a time-dependent in-
crease in the proportion of PIGA
 
 
 
 cells in all blood cell lin-
eages and generated for the first time mice that have almost
all blood cells deficient in GPI-linked proteins. Progenitor
analysis and bone marrow transplantation experiments
demonstrate that 
 
Piga
 
 inactivation in these mice occurs in
HSCs of the bone marrow.
 
Materials and Methods
 
Mice.
 
The production of 
 
loxPiga
 
 (L) mice was described pre-
viously (see Fig. 1 A) (22). The 
 
fes-cre 
 
(F) mice (see Fig. 1 B) were
generated by using the 13-kb EcoRI fragment encompassing hu-
man 
 
c-fes
 
 (19). An NdeI site in the noncoding region of exon 19
was first converted to a unique EcoRV site by digestion with
NdeI, recessing the 3
 
 
 
 end with T4 DNA polymerase, and then
annealing and ligating with the adapter linkers 5
 
 
 
-CCA GCT
CAT AGA TAT C-3
 
 
 
 and 5
 
 
 
-TGT CAG CAT AGA TAT C-3
 
 
 
.
The poliovirus type 2 internal ribosome entry site (IRES) be-
tween nucleotides 125 and 720 (Lansing strain; GenBank/
EMBL/DDBJ accession no. M12197) was PCR amplified using
primers containing SmaI (5
 
 
 
-CAC AAG CTT CCC GGG CAA
GTT CAA TAG GAG-3
 
 
 
) and EcoRV sites (5
 
 
 
-AGA CCC
GGG ATA TCT GGT AAT TCC AAT AGG TG-3
 
 
 
). The
IRES-containing PCR fragment was digested with SmaI and
EcoRV and cloned into the unique EcoRV site in the 3
 
 
 
 non-
coding region of the 
 
c-fes 
 
gene within the pECE expression plas-
mid (23) to produce pEFOR-5. The CreN coding sequence
from pTZ-CreN was excised as a HindIII to EcoI fragment,
blunt ended with Klenow fragment, and cloned into the EcoRV
site of pEFOR-5 to produce pEFOR-CreN.
 
 
 
The 
 
fes-cre
 
 fragment
was excised as an EcoRI fragment and injected into CBA/ca 
 
 
 
C57Bl/6 F1 fertilized eggs (E. Lacy, Transgenic Core Facility,
Memorial Sloan-Kettering Cancer Center, New York, NY).
Founder mice were identified by Southern blot, and double
transgenic mice (LF mice) by PCR analysis. Three F founder
lines (nos. 16, 31, and 40) were evaluated. Tissue distribution of
 
Piga
 
 gene inactivation was similar, but the kinetics were copy
number dependent. Thus, for the following experiments, line
 
 
 
31
with the highest copy number (30 copies) was used.
 
 
 
Initial exper-
iments were performed in a mixed genetic background and later
confirmed with mice in a C57Bl/6 
 
n
 
 
 
  
 
10 background. F and L
littermates were used as controls. All experiments involving ani-
mals were approved by the Animal Studies Committee of Wash-
ington University.
 
DNA Amplification and Southern Blot Analysis.
 
Genotyping by
PCR and Southern blot were performed as described (24). The
intensity of the 
 
cre
 
 hybridization signal was used to identify prob-
able 
 
fes-cre
 
 homozygous animals. For the isolation of tissue DNA
animals were perfused with PBS.
 
Flow Cytometric Analysis.
 
Flow cytometric analysis
 
 
 
was per-
formed as described (8). Monoclonal antibodies used against
GPI-linked proteins were CD24(M1/69), Gr-1(RB6-8C5), and
CD48(HM48-1). Lineage specificity was analyzed by the use of
antibodies against CD11b(M1/70), B220(RA3-6B2), TcR(H57-
597), CD4(GK1.5), CD8(53-6.7), Ter119(TER-119), CD71(C2),
c-kit(2B8), and CD34(RAM34). A mixture of PE-labeled anti-
bodies against CD3(145-2C11), CD4, CD5(53-7.3), CD8, B220,
CD11b, and Ter119 was used to exclude lineage-committed
bone marrow cells. CD45.2(104) was used to determine the
CD45 allotype. Reticulocyte counts and blood values were de-
termined as described (22).
 
Analysis of 
 
 
 
-Gal Expression.
 
Anesthetized mice were per-
fused with 2% paraformaldehyde, 0.2% glutaraldehyde in PBS.
Small organ pieces were postfixed for 60 min and stained for lacZ
expression as described by Sanes et al. (25). Incubation was for
24 h at 37
 
 
 
C.
 
Clonogenic Assays.
 
Fetal liver cells from embryonic day
(E)12.5 or E18.5 embryos and adult bone marrow cells were
plated in methylcellulose (MethoCult™ M3434; StemCell Tech-
nologies Inc.). Colonies were counted after 7–10 d. Visual in-
spection, light scatter characteristics, and the expression of CD71
and CD11b were used to characterize individual colonies.
 
Aerolysin Treatment.
 
Mouse femora were flushed with HBSS
containing 2% isogenic mouse serum. 6 
 
  
 
10
 
6
 
 cells in a final vol-
ume of 500 
 
 
 
l 2% mouse serum-HBSS were incubated for 30
min at 37
 
 
 
C with no, 10 nM, or 50 nM aerolysin (Thomas
Buckley, University of Victoria, Victoria, Canada). In prelimi-
nary in vitro experiments 10 and 50 mM concentrations demon-
strated efficient lysis of PIGA
 
 
 
 but not PIGA
 
 
 
 hematopoietic
progenitor cells.
 
Bone Marrow Transplantation.
 
All mice were in C57Bl/6
background.
 
 
 
We used the CD45.2/45.1 allotype system to distin-
guish donor and recipient blood cells. Recipient mice and bone
marrow cells for radioprotection were CD45.1 (B6.SJL-Ptprc
 
a
 
Pep3
 
b
 
/BoyJ mice; The Jackson Laboratory), and donor cells for
aerolysin treatment were CD45.2. Recipient mice were irradi-
ated with a single dose of 10 Gy the day before marrow injection.
10
 
6 
 
aerolysin-treated or sham-treated cells (as counted before
treatment) and 0.5 
 
  
 
10
 
6 
 
untreated radioprotection cells in a total
volume of 300 
 
 
 
l HBSS were injected into lateral tail veins.
 
Results
 
Generation of fes-cre Mice.
 
To target Cre-mediated 
 
Piga
 
gene inactivation to early hematopoietic cells we expressed
the Cre recombinase under the LCR of the human 
 
c-fes
 
gene (20; Fig. 1 B). In double transgenic mice, Cre-medi-
ated recombination of the 
 
loxPiga
 
 allele deletes part of 
 
Piga
 
exon 2, which abolishes the function of PIGA (22; Fig. 1
A). 
 
Piga
 
 maps to the X chromosome and is subject to X 
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chromosome inactivation (24). Thus, in males the inactiva-
tion of the one 
 
Piga
 
 allele is sufficient to cause the loss of
GPI-linked proteins on the cell surface. In females the in-
activation of the 
 
Piga
 
 allele when it is on the active
X-chromosome will lead to the loss of GPI-linked proteins
on the cell surface (due to random X-inactivation this is
expected to occur in about half of the cells). LF mice were
born with the expected frequency and were indistinguish-
able from their littermates that only inherited one trans-
gene. 16 LF mice (9 males and 7 females) were monitored
over a time period of 12–16 mo.
 
LF Mice Have Increasing Numbers of Circulating PIGA
 
 
 
Blood Cells.
 
To monitor the proportion of PIGA
 
 
 
 cells in
peripheral blood, we analyzed the expression of GPI-linked
proteins by flow cytometry. Analysis of red cells 1 to 3 d af-
ter birth showed a small but distinct proportion of PIGA
 
 
 
cells (average 1.4%, range 0.1–12.5%). Over the following
months, the proportion of PIGA
 
 
 
 red cells increased con-
tinuously in all LF animals and by the age of 16 mo the
proportion of PIGA
 
 
 
 red blood cells reached up to 94%
(average 52%,
 
 
 
5–94%, 
 
n 
 
  
 
10; Fig. 2 A). A similar contin-
uous increase of PIGA
 
  cells was found in white blood
cells. At the age of 1 mo, the proportion of PIGA  cells
was 27% in granulocytes (11–49%), 14% in B cells (5–
22%), and 20% in T cells (7–34%). At 16 mo the propor-
tions of PIGA  cells increased to 69% (41–97%) in granu-
locytes, 56% (26–83%) in B cells, and 77% (64–87%) in T
cells. No PIGA  blood cells were detected in control mice
( 1%, data not shown). In female mice the proportion of
PIGA  blood cells was always lower than in male mice.
This is consistent with random X chromosome inactivation
in female somatic cells causing only half of the cells to ex-
press the recombined Piga gene (Fig. 2, A and B). Fig. 2 B
shows the relative level of PIGA  cells for all four blood
cell lineages and the proportion of PIGA  reticulocytes
measured at the age of 4 (45%, 34–57%), 8 (53%, 24–74%),
and 16 (66%, 33–97%) mo. The proportion of PIGA  red
blood cells was significantly lower than PIGA  reticulo-
cytes in all animals analyzed, which is consistent with the
shortened half-life of PIGA  red cells in circulation (22).
We have previously shown that PIGA  red cells from mice
mosaic for a nonfunctional Piga gene have an increased
sensitivity to complement (22). Similarly, also PIGA  red
cells from LF mice showed an increased lysis when exposed
to complement (data not shown), suggesting that the de-
creased half-life of PIGA  red cells is due to the action of
complement. Within the white blood cells the percentage
of PIGA  cells was consistently lower in B cells than in any
other cells.
Fes-cre Homozygosity Accelerates Rate of Piga Recombina-
tion. To test whether an increase in the fes-cre transgene
copy number will accelerate the rate of Cre-mediated lox-
Piga recombination we crossbred female LF mice with
male mice homozygous for fes-cre. In 12 mice positive for
loxPiga and homozygous for fes-cre (LFF mice) the propor-
tions of PIGA  red blood cells were higher and the in-
crease faster than in LF mice. A similar rapid increase of
PIGA  cells was also found within granulocytes, B cells,
and T cells. These data indicate that the rate of loxPiga re-
combination in LFF mice is accelerated (Fig. 2 C). For the
first time we were able to generate mice with almost 100%
of PIGA  blood cells (Fig. 2 D).
FES-Cre–mediated Recombination of the loxPiga Allele in Fe-
tal Hematopoiesis. To test whether recombination of the
loxPiga allele occurs also in primitive hematopoiesis,  we
collected genotyped fetuses from timed pregnancies. At day
E12.5, 90% of circulating red blood cells are nucleated
primitive red blood cells derived from yolk sac erythro-
poiesis. Analysis of GPI-linked proteins on primitive red
cells did not reveal a significant difference between control,
LF, and LFF fetuses, suggesting that FES-Cre does not me-
diate recombination of the loxPiga allele in hematopoietic
progenitors of primitive red cells. However, in fetuses of
E18.5 whose circulating red blood cells are derived from
definitive hematopoiesis we found a distinct population of
PIGA  red blood cells in 5 out of 16 LF and LFF fetuses
(Fig. 3). Clonogenic progenitor assays similarly revealed no
PIGA  colonies from fetal liver cells of 12 E12.5 LF fe-
tuses. In contrast, cultures from fetal liver cells from all five
E18.5 LF fetuses with PIGA  red cells grew PIGA  colo-
nies with differentiation into the erythroid and my-
elomonocytic lineage (data not shown), indicating that
progenitors with a recombined loxPiga allele reside in fetal
livers of E18.5 but not in fetal livers of E12.5 embryos.
Tissue Distribution of PIGA  Cells in LF Mice. The pro-
portion of PIGA  cells found in bone marrow, spleen, and
lymph nodes from four LF mice are summarized in Fig. 4
A. Recombination of the loxPiga allele in nonhematopoi-
etic tissues was determined by Southern blot analysis. Rep-
resentative Southern blots of a 2- and 8-mo-old male LF
Figure 1. Fes-cre and loxPiga mice. (A) Genomic structure of the wt
Piga, loxPiga, and  Piga allele (loxPiga after recombination). Two loxP
sites (triangles) and the coding region for lacZ were introduced into the
Piga locus by homologous recombination in embryonic stem (ES) cells
(reference 22). In the loxPiga configuration, PIGA function is not im-
paired (black boxes) and LacZ is not expressed (empty lacZ box). How-
ever, after Cre-mediated excision of the DNA sequence between the two
loxP sites, Piga becomes inactive (empty Piga boxes) and lacZ falls under
the endogenous Piga promoter and is expressed (black lacZ box). (B)
Transgenic construct of fes-cre.  Cre  with a nuclear localization signal
(CreN) was cloned into the 3  untranslated region of human c-fes gene.
The expression of fes-cre is maintained by an IRES, resulting in a bicis-
tronic message under the control of the human c-fes LCR. E, EcoRI; RV,
EcoRV.584 PIGA Inactivation in Hematopoietic Stem Cells
mouse are shown in Fig. 4 B. The strongest hybridization
signal specific for  Piga was detected in hematopoietic or-
gans including bone marrow, spleen, thymus, and lymph
nodes. Nonhematopoietic organs, including liver, lung,
kidney, gut, brain, and cerebellum, showed no or only a
faint hybridization signal for  Piga. A slightly stronger
 Piga hybridization signal was detected in heart and muscle
tissue and in older animals also in lung, kidney, and brain.
All mice were healthy until the age of about 12 mo.
There were no obvious signs of anemia, hemoglobinuria,
or thrombosis. In mice with a high proportion of PIGA 
red cells the hemoglobin values, although still within nor-
mal limits, were lower then in control mice, whereas the
reticulocyte counts were higher. The absolute neutrophil,
B, and T cell counts did not differ between mice with a
high proportion of PIGA  blood cells and normal mice at
all times analyzed (see also Table I). At the age of 12 mo,
male LF mice developed neuromuscular symptoms includ-
ing weight loss, decreased overall activity, general muscular
weakness, and a wide gait. Neuromuscular symptoms were
observed in all male LF mice but not in female LF mice nor
in control mice. Histological examination of brain and
skeletal muscle from the affected male mice showed no ob-
vious pathological changes. We cannot exclude selective
neuronal loss or damage to a small subpopulation of central
Figure 2. Proportions of PIGA  cells in peripheral blood from LF and LFF
mice. (A) 16 mo follow-up of the proportion of PIGA  blood cells in LF
mice (females n   6, males n   9). (B) Comparison of the relative number of
PIGA  cells in different blood cell lineages in LF mice. Each data point rep-
resents the average value from six female and nine male mice. (C) Proportion
of PIGA  blood cells in three male LFF mice. The gray-shaded area repre-
sents the proportions of PIGA  cells between the 10th and 90th percentile in
male LF animals for comparison. (D) Flow cytometric analysis of peripheral
blood cells from an 8-mo-old male LFF mouse with 100% PIGA  red cells,
99% PIGA  granulocytes, 93% PIGA  B cells, and 94% PIGA  T cells. Most
of the few remaining PIGA  B and T cells were CD44high and CD62Llow
(data not shown), suggesting that they are mainly long lived memory cells.
Monoclonal antibodies against CD24, GR-1, and CD48 were used as mark-
ers for GPI-linked proteins. Antibodies identifying the blood cell lineage
were CD11b for granulocytes, B220 for B cells, and TcR for T cells. Red
blood cells were identified by their light scatter characteristics. The top left
quadrant shows the proportion of PIGA  cells for each blood cell lineage.
Figure 3. PIGA  blood cells during embryogenesis. Percentage of
PIGA  red blood cells in LF ( ) and LFF ( ) fetuses at embryonic day
E12.5 and E18.5. Circulating red blood cells were analyzed for the ex-
pression of CD24. The horizontal lines represent the means.585 Keller et al.
or peripheral neurons; however, no global abnormalities in
nervous system structure were found to account for the ob-
served symptoms. Neuromuscular symptoms also devel-
oped in LF mice transplanted with normal bone marrow
cells, but did not occur in wild-type (wt) mice transplanted
with PIGA  bone marrow cells. This suggests that neuro-
muscular symptoms were not due to the high number of
PIGA  blood cells. To test for loxPiga recombination in in-
dividual neurons we assayed sections of the brain from a
12-mo-old LF male for  -galactosidase activity. Small
groups of neuronal cells with blue staining nuclei were
found particularly in the thalamus (data not shown), indi-
cating that PIGA inactivation occurs in specialized neurons.
Some LF mice older than 12 mo developed hemangio-
mas and B cell lymphomas in spleen and lymph nodes.
Identical tumors were also observed in F mice from two
different founder lines, indicating that they were caused by
the expression of FES-Cre.
Recombination of the loxPiga Allele in LF Mice Occurs in
c-kit CD34 Lin  Progenitor Cells before the GEMM Stage.
To identify the earliest cell stage of differentiation that lacks
GPI-linked proteins due to an inactive Piga gene, we ana-
lyzed the c-kit Lin  and CD34 Lin  bone marrow cells
for the expression of GPI-linked proteins. In control mice,
only 7% (2–18%, n   4) of c-kit Lin  cells and 10% (2–
19%, n = 3) of CD34 Lin  cells were deficient in CD24.
In contrast, in four LF mice the proportion of CD24-nega-
tive cells was 75%  (71–79%) in c-kit Lin  and 91%
(83–96%) in CD34 Lin  bone marrow cells (Fig. 5). In-
terestingly, the proportion of c-kit Lin  and CD34 Lin 
progenitor cells in all four LF mice was larger than in con-
trol animals. This might be explained by an increased and
left shifted erythropoiesis in LF mice due to the shortened
half-life of PIGA  red cells (22). Experiments investigating
hemolysis in LF mice are currently ongoing. To further de-
termine the stage of hematopoietic differentiation in which
FES-Cre–mediated recombination occurs, we next per-
formed progenitor culture assays. Table II summarizes the
expression of GPI-linked proteins in 313 individual CFUs
grown from bone marrow cells of seven LF animals. The
majority of colonies consisted of either PIGA  cells or
PIGA  cells. Only 4 out of 75 CFU-GEMM colonies
were mixed colonies with cells expressing and cells lacking
GPI-linked proteins. These results suggest that recombina-
tion of the loxPiga allele occurs mostly before the CFU-
GEMM stage. As for the few mixed colonies, we cannot
determine conclusively whether loxPiga recombination oc-
curred during the maturation of the individual colony, or if
they are due to the accidental close seeding of two progen-
itor cells. The finding that in all four mixed CFU-GEMMs
the proportion of PIGA  cells were the same in myeloid
and erythroid cells supports the latter.
PIGA  Cells in LF Mice Have Long-Term Repopulating
Abilities. We next tested whether LF mice have PIGA 
hematopoietic progenitor cells that have long-term bone
marrow repopulating potential. To enrich for PIGA  cells
we incubated bone marrow cells with the toxin aerolysin
that selectively lyses wt cells (26).  First, we transplanted
Figure 4. Distribution of PIGA  cells in different organs. (A) Propor-
tion of PIGA  red, myeloid, B, and T cells in peripheral blood, spleen,
lymph nodes, and bone marrow in LF mice as determined by flow cy-
tometry. The horizontal line indicates the mean of the proportion of
PIGA  cells in four 6-mo-old male LF mice, each value is represented by
an individual dot. RBC, red blood cells; Reti, reticulocytes; Sp, spleen;
BM, bone marrow; PB, peripheral blood. (B) LoxPiga recombination in
various organs. Southern blot analysis was used to determine degree of
loxPiga recombination in different organs of male LF mice. The top panel
represents a 2-mo-old and the bottom panel an 8-mo-old LF mouse.
DNA was digested with PstI, and blots hybridized with a Sac-Bam Piga
DNA probe. The 10.4-kb fragment corresponds to loxPiga and the 8.1-kb
fragment to  Piga. Sp, spleen; Th, thymus; Ln, node; Bm, bone marrow;
Li, liver; H, heart; Lu, lung; K, kidney; G, gut; M, muscle; T, testis; B,
brain; C, cerebellum.
Table I. Blood Values in Control, LF, and LFF Mice at 8 Mo of Age
Animal Hemoglobin Retis Platelets PMN B cells T cells
g/dl % 103/ l1 0 3/ l1 0 3/ l1 0 3/ l
Controls  (n   11) 14.6   0.7 4.1   0.7 1,244   114 1.9   1.0 3.2   1.4 1.8   0.5
LF males  (n   11) 13.5   1.4a 5.2   1.7 1,520   165a 1.8   0.8 4.0   1.3 2.2   0.8
LFF males  (n   11) 12.7   1.2a 6.2   1.5a 1,184   561a 1.2   1.0 3.7   2.5 2.2   1.2
aValues significantly different from age-matched controls (P   0.05).586 PIGA Inactivation in Hematopoietic Stem Cells
aerolysin-treated and sham-treated bone marrow cells from
wt mice (Fig. 6 A). In these experiments, the treated cells
were from a CD45.2  mouse and were transplanted along
with untreated cells from a CD45.1  mouse to ensure sur-
vival. The ability of the treated cells to engraft is monitored
by measuring the engrafted CD45.2 cells. 1 and 3 mo after
transplantation only low numbers of donor-derived aero-
lysin-treated cells were detected in the peripheral blood of
recipient mice (1 mo: average 7.2%, range 5.6–10.0%; 3
mo: average 4.2%, 3.4–5.5%, n   4). In contrast, in two
mice transplanted with sham-treated marrow cells, 62 and
69%  of white blood cells  were donor derived, which is
consistent with the ratio of transplanted donor cells and
cells injected for radioprotection. These findings demon-
strate that aerolysin efficiently lyses HSCs from wt mice.
Next, we transplanted aerolysin- and sham-treated bone
marrow cells from a female LF mouse. 1 mo after trans-
plantation, analysis of recipient mice that have received
bone marrow cells treated with aerolysin revealed 45% do-
nor chimerism (32–55%) with 93% (89–96%, n   6) of
PIGA  white blood cells (Fig. 6 B). 3 mo after transplanta-
tion high donor chimerism (72%, 65–83%) and the high
proportion of PIGA  cells (97%, 95–97%) persisted. Mice
receiving sham-treated LF bone marrow cells showed 59
and 80% of donor chimerism, with only 43 and 53% do-
nor-derived PIGA  cells 1 and 3 mo after transplantation
(Fig. 6 B). Finally, in secondary transplantation experi-
ments, the donor chimerism was stable (average 90%, range
87–94%, n   3), and 99.3, 99.4, and 99.6% of LF donor-
derived cells were deficient in GPI-linked proteins 4 mo
after transplantation.
Discussion
In patients with PNH, a somatic mutation of the PIGA
gene occurs in a multipotent progenitor cell that probably
is a HSC (3, 4). To further study the pathogenesis and
pathophysiology of this disorder and to develop a possible
cure, a mouse model would be invaluable. Here we report
Figure 5. Proportions of PIGA  bone marrow progenitor cells. Bone
marrow mononuclear cells were stained with antibodies against c-kit or
CD34 and an antibody mixture to exclude lineage-committed cells.
CD24 was used as a marker for GPI-linked proteins. The c-kit Lin  and
CD34 Lin  progenitors from LF (top panel) and control (bottom panel)
mice are displayed in the top left quadrant of the first and third dot blot,
respectively. The second and fourth dot blot in each panel is gated for lin-
eage negative cells (Lin ). PIGA  c-kit Lin  progenitors (LF 79%, con-
trol 3%) are displayed in the top left quadrant of the second dot blot,
PIGA  CD34 Lin  progenitors (LF 88%, control 2%) are displayed in
the upper left quadrant of the forth dot blot.
Table II. PIGA Phenotype of CFUs in Clonogenic Assays
Colonies BFU-E CFU-GM CFU-G CFU-GEMM
Total
CFU
PIGA  25 46 58 39 168
PIGA  24 45 36 32 137
Mixed 1 1 2 4 8
Total 50 92 96 75 313
BFU-E, burst-forming unit erythroid; G, granulocytes; GEMM,
granulocytes, erthyrocytes, megakaryocytes, monocytes.
Figure 6. Bone marrow reconstitution using aerolysin-treated bone
marrow cells. (A) Donor chimerism after aerolysin treatment of wt bone
marrow cells. 106 bone marrow cells of a CD45.2  wt mouse were incu-
bated with aerolysin and injected into lethally irradiated recipient mice of
the CD45.1 allotype. 10 and 50 nM concentrations of aerolysin were
used. 0.5   106 nonirradiated, congenic CD45.1  marrow cells were
given simultaneously for radioprotection. Peripheral blood cells of recipi-
ents (n   4) were analyzed by flow cytometry. Columns represent the
proportion of donor-derived chimerism (percentage of CD45.2  cells).
(B) Bone marrow reconstitution with PIGA  cells. 106 marrow cells of a
female CD45.2  LF mouse (red blood cells 19%, granulocytes 37%, B
cells 19%, and T cells 52% PIGA  cells) were incubated with aerolysin
and transplanted into lethally irradiated CD45.1  recipient mice (n   6).
0.5   106 nonirradiated, CD45.1  marrow cells were coinjected for ra-
dioprotection. The top panel represents the proportion of donor-derived,
CD45.2  cells. The bottom panel shows the proportion of donor-derived
CD45.2  cells that lack GPI-anchored surface molecules. Shown are the
means with standard deviations. Gc, granulocytes; B, B cells; T, T cells.587 Keller et al.
on the generation of a mouse line in which a somatic mu-
tation leads to PIGA  cells in all blood cell lineages. In
contrast to our previously reported mice which were mo-
saic for cells with an inactive Piga gene and had only very
low numbers of PIGA  cells in peripheral blood limiting
the possibility of functional studies (22), we have now pro-
duced animals that have almost exclusively PIGA  blood
cells. Analysis of hematopoietic progenitors demonstrates
that in our LF mice inactivation of the Piga gene occurs in
the HSC.
We chose to express the Cre recombinase under the
c-fes LCR because of known high expression of FES in
early myeloid progenitor cells (12, 13) and the conve-
nience of using an LCR for the expression of a transgene.
As the Piga gene is on the X chromosome, only a single
Cre-mediated recombination event is required to cause
the loss of GPI-linked proteins on the cell surface. In the
case of females, the loss only occurs when the recombined
allele is on the active X chromosome. Guided by previous
expression of human FES by the c-fes LCR in transgenic
animals (20, 21), we expected a predominantly myelo-
monocyte–specific expression of the PIGA  phenotype in
LF animals. Thus, the constant time-dependent increase
of PIGA  cells in all blood cell lineages including the
erythroid lineage (Fig. 2, A and B) was a surprise. In LF
mice the loss of GPI-linked proteins occurred for the ma-
jority of hematopoietic cells in c-kit CD34 Lin  pro-
genitor cells before the CFU-GEMM stage of differentia-
tion. No additional Piga gene inactivation was found in
vitro in clonogenic progenitors during myeloid differenti-
ation (Table II). The increased proportion of PIGA 
granulocytes in peripheral blood compared with the bone
marrow (Fig. 4 A), however, might indicate low level
Piga gene inactivation in vivo during myeloid differentia-
tion. Alternative explanations would be early release of
PIGA  granulocytes or a prolonged survival in circula-
tion. Functional studies of PIGA  blood cells are on-
going.
Southern blot analysis suggests that FES-Cre–mediated
Piga gene inactivation occurs predominantly, although not
exclusively, in hematopoietic cells. Old LF mice have
stronger  Piga specific hybridization signals in nonhemato-
poietic organs compared with young LF animals, suggest-
ing the slow accumulation of a small proportion of PIGA 
cells in various tissues. In some organs, such as the lung and
gut, this might be due to increasing lymphocytic infiltrates
in older animals. In other tissues, such as the heart, this is
more likely due to loxPiga recombination in non-hemato-
poietic cells, for example the vascular endothelium. How-
ever, we did not detect  -galactosidase activity in endothe-
lial nuclei (data not shown). In contrast, recombination of
the loxPiga allele was found in neuronal cells, causing a
neuromuscular deficit in aging male LF mice. We can not
exclude that low level of loxPiga recombination occurs in
additional cells that due to the loss of GPI-linked proteins
die and thus are not accounted for. However, necropsy of
24 mice did not reveal any macroscopic or histological ab-
normalities.
Two characteristics define a HSC. First, they have the
potential to differentiate into all blood cell lineages. Sec-
ond, they can generate more stem cells, a process of self-
renewal. To test whether PIGA  HSCs exist in LF mice,
bone marrow reconstitution experiments were designed to
allow purified donor-derived PIGA  hematopoiesis to be
evaluated over the course of several months. In the pres-
ence of a radioprotective dose of adult bone marrow cells,
aerolysin-treated marrow cells competed for hematopoiesis
in irradiated recipient mice. Aerolysin is a pore-forming
toxin from Aeromonas hydrophilia that needs to bind to GPI-
anchored surface proteins of target cells to develop lytic ac-
tivity (26). Wt aerolysin-treated cells were efficiently out-
competed, indicating that aerolysin efficiently lyses wt bone
marrow stem cells (Fig. 6 A). In contrast, blood cells de-
rived from aerolysin treated cells of LF mice were found at
levels up to 45% for more than 3 mo and were almost ex-
clusively of the PIGA  phenotype (Fig. 6 B). The propor-
tion of LF-derived cells corresponds to the proportion of
radioprotective cells and aerolysin-resistant PIGA  he-
matopoietic cells transplanted. This demonstrates that LF
mice have PIGA  bone marrow cells that efficiently com-
pete for hematopoiesis in an irradiated recipient mouse.
Long-term repopulation ability of PIGA  cells was demon-
strated by secondary transplantation experiments leading to
persistent PIGA  hematopoiesis in secondary recipient
mice. These findings prove unambiguously that LF mice
have PIGA  HSCs and that recombination of the loxPiga
allele must occur in HSCs. Inactivation of PIGA in blood
cells of LF mice is the first clear demonstration of transgene
expression in HSCs. Interestingly, loxPiga recombination
was not found in red blood cells derived from primitive he-
matopoiesis, suggesting that FES-Cre causes recombination
of the loxPiga allele in HSCs from definitive but not from
primitive hematopoiesis.
Our findings of FES-Cre–mediated loxPiga recombina-
tion differ significantly from the myelo-monocyte–specific
transgene expression of the human c-fes LCR reported pre-
viously (20, 21, 27). We can think of several explanations.
First, Cre-mediated recombination of the loxPiga allele is
irreversible and thus is very sensitive in tracing Piga gene
inactivation in a small population of progenitor cells that
might be easily missed in the analysis of a temporarily ex-
pressed transgene. Second, a certain threshold level of Cre
might be required for successful recombination of the lox-
Piga allele, which might only be reached in a small number
of stem cells, but not in rapidly dividing myeloid progeni-
tors. Third, the loss of Piga gene function in end-differenti-
ated, short lived, nondividing cells might not become ap-
parent due to the long half-life of many GPI-linked
proteins (28, 29). Although transgene expression in mice
via a human LCR not necessarily mirrors human or murine
gene expression in vivo, our findings suggest that FES in
addition to its previously described expression pattern
might also be expressed in HSCs of definitive hematopoie-
sis. The isolation of murine c-fes messenger RNA in cells
enriched for murine liver stem cells (18) and the defect in
bone marrow HSCs identified in PU.1-deficient mice (30),588 PIGA Inactivation in Hematopoietic Stem Cells
PU.1 being the main transcription factor that regulates c-fes
gene expression (31), support this hypothesis.
LF mice with almost 100% of PIGA  blood cells have
lower hemoglobin levels and higher reticulocyte counts
compared with normal mice. However, in contrast to pa-
tients with PNH, LF mice do not develop obvious anemia,
hemoglobinuria, or thrombosis. Investigations are currently
ongoing to test whether the comparatively modest decrease
in hemoglobin levels is due to the low hemolytic activity of
complement in C57Bl/6 mice or rather caused by the ex-
pression of an additional complement regulatory protein in
mice, Crry, which is a transmembrane protein and thus is
not affected by the lack of GPI-anchor molecules. White
blood cell values and platelet counts in LF mice were nor-
mal (Table I), indicating that PIGA  HSCs are able to
maintain normal blood cell values. Thus, our LF mice
demonstrate that pancytopenia, in particular thrombocy-
topenia, which are often found in patients with PNH, are
not due to the lack of GPI-linked proteins, but rather
caused by the underlying bone marrow failure that accom-
panies or precedes PNH. In contrast to our previous mouse
model for PNH (22), FES-Cre–mediated recombination of
the loxPiga allele provides us with mice that due to a so-
matic mutation in HSCs in the bone marrow have high
percentages of PIGA  blood cells in all blood cell lineages.
In this respect, LF mice mimic accurately the situation of
PIGA  cells in patients with PNH. Mice with almost ex-
clusively PIGA  blood cells promise to be a powerful new
tool to investigate the functional consequences caused by
the loss of GPI-linked proteins in hematopoiesis, immuno-
surveillance, and leukemogenesis. In addition, the possibil-
ity to easily and reproducibly target gene expression to
HSCs using the human c-fes LCR promises new and excit-
ing possibilities in stem cell biology.
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